STOCK TITAN

Whitehawk Therapeutics to Participate in the TD Cowen 6th Annual Oncology Innovation Summit

Whitehawk Therapeutics (NASDAQ: WHWK), an oncology therapeutics company focused on ADC cancer treatments, announced that its CEO Dave Lennon, PhD, will participate in a fireside chat at the TD Cowen 6th Annual Oncology Innovation Summit.

(Moderate)

Sentiment and the balance of points

Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.

Tags
conferences

Whitehawk Therapeutics (NASDAQ: WHWK), an oncology therapeutics company focused on ADC cancer treatments, announced that its CEO Dave Lennon, PhD, will participate in a fireside chat at the TD Cowen 6th Annual Oncology Innovation Summit. The event is scheduled for May 28, 2025, at 2:30 PM ET. Investors can access the live webcast through Whitehawk's IR website, with the recording remaining available for approximately 30 days after the event.

[]
Loading...
Loading translation...
Argus Session date unavailable
-3.27% session move Open Argus
Details

News Market Reaction – WHWK

The recorded move for WHWK in the trading session of this news was -3.27%.

Data tracked by StockTitan Argus. Session date unavailable.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google
Add on Google

MORRISTOWN, N.J., May 21, 2025 /PRNewswire/ -- Whitehawk Therapeutics, Inc. (Nasdaq: WHWK), an oncology therapeutics company applying advanced technologies to established tumor biology to efficiently deliver improved ADC cancer treatments, announced today the Company's president and CEO, Dave Lennon, PhD, will participate in a fireside chat at the TD Cowen 6th Annual Oncology Innovation Summit: Insights for ASCO & EHA, on May 28, 2025, at 2:30 PM ET. 

A live webcast of the fireside chat can be accessed by visiting the Whitehawk Therapeutics IR website and will be available for replay for approximately 30 days following the event.

About Whitehawk Therapeutics 

Whitehawk Therapeutics is an oncology therapeutics company applying advanced technologies to established tumor biology to efficiently deliver improved cancer treatments. Whitehawk's advanced three-asset ADC portfolio is engineered to overcome the limitations of first-generation predecessors to deliver a meaningful impact for patients with difficult-to-treat cancers. These assets are in-licensed from WuXi Biologics under an exclusive development and global commercialization agreement. More information on the Company is available at www.whitehawktx.com and connect with us on LinkedIn.

Contact:
IR@whitehawktx.com

Whitehawk Therapeutics, Inc. logo (PRNewsfoto/Whitehawk Therapeutics, Inc.)

Cision View original content to download multimedia:https://www.prnewswire.com/news-releases/whitehawk-therapeutics-to-participate-in-the-td-cowen-6th-annual-oncology-innovation-summit-302461639.html

SOURCE Whitehawk Therapeutics, Inc.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

When is Whitehawk Therapeutics (WHWK) presenting at the TD Cowen Oncology Summit 2025?

Whitehawk Therapeutics' CEO will participate in a fireside chat on May 28, 2025, at 2:30 PM ET during the TD Cowen 6th Annual Oncology Innovation Summit.

Who will represent Whitehawk Therapeutics (WHWK) at the TD Cowen Oncology Summit?

Dave Lennon, PhD, President and CEO of Whitehawk Therapeutics, will represent the company at the summit.

How can investors access Whitehawk Therapeutics' (WHWK) presentation at the TD Cowen Summit?

Investors can access the live webcast through Whitehawk Therapeutics' IR website, and a replay will be available for approximately 30 days following the event.

What is Whitehawk Therapeutics' (WHWK) main business focus?

Whitehawk Therapeutics is an oncology therapeutics company that applies advanced technologies to established tumor biology to efficiently deliver improved ADC cancer treatments.

Keep reading